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ABSTRACT 
Background 
The efficacy and safety of palbociclib, a cyclin-dependent kinase 4/6 inhibitor, combined with 
fulvestrant and goserelin was assessed in premenopausal women with advanced breast cancer 
(ABC) who had progressed on prior endocrine therapy (ET). 
Patients and Methods 
108 premenopausal endocrine-refractory women ≥18 years with HR+/HER2 ABC were among 
521 women randomized 2:1 (347:174) to fulvestrant (500 mg) ± goserelin with either palbociclib 
(125 mg/d orally, 3 weeks on, 1 week off) or placebo. This analysis assessed whether the overall 
tolerable safety profile and significant progression-free survival (PFS) improvement extended to 
premenopausal women. Potential drug-drug interactions (DDIs) and ovarian suppression with 
goserelin were assessed via plasma pharmacokinetics and biochemical analyses, respectively.  
Results 
Median PFS for premenopausal women in the palbociclib (n=72) vs placebo arm (n=36) was 9.5 
vs 5.6 months, respectively (hazard ratio, 0.50, 95% CI: 0.290.87), and consistent with the 
significant PFS improvement in the same arms for postmenopausal women. Any grade and grade 
≤3 neutropenia, leukopenia, and infections were among the most frequent adverse events 
reported in the palbociclib arm with concurrent goserelin administration. Hormone 
concentrations were similar between treatment arms and confirmed sustained ovarian 
suppression. Clinically relevant DDIs were not observed. 
Conclusion 
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Palbociclib combined with fulvestrant and goserelin was an effective and well-tolerated 
treatment for premenopausal women with prior endocrine-resistant HR+/HER2 ABC. Inclusion 
of both premenopausal and postmenopausal women in pivotal combination ET trials facilitates 
access to novel drugs for young women and should be considered as a new standard for clinical 
trial design. 
 
ClinicalTrials.gov NCT01942135 
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Implications for Practice 
PALOMA-3, the first registrational study to include premenopausal women in a trial 
investigating a CDK4/6 inhibitor combined with endocrine therapy, has the largest 
premenopausal cohort reported in an endocrine-resistant setting. In pretreated premenopausal 
women with HR+ ABC, palbociclib plus fulvestrant and goserelin (LHRH agonist) treatment 
almost doubled median PFS and significantly increased the objective response rate vs endocrine 
monotherapy, achieving results comparable to those reported for chemotherapy without 
apparently interfering with LHRH agonist-induced ovarian suppression. The significant PFS gain 
and tolerable safety profile, strongly supports use of this regimen in premenopausal women with 
endocrine-resistant disease who could possibly delay chemotherapy. 
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Learning Objectives 
BEST PRACTICE CURRENT PRACTICE RESULTING GAPS LEARNING OBJECTIVES 
Premenopausal women with HR+ MBC 
should be offered ovarian suppression or 
ablation in combination with hormone 
therapy.  
For premenopausal patients whose 
disease progresses on prior endocrine 
therapy, and for whom subsequent 
hormone therapies are indicated for their 
MBC, ovarian suppression should be 
maintained during treatment. 
Measurements of estradiol and FSH at 
baseline, before a premenopausal patient 
initiates treatment with a LHRHa and 
aromatase inhibitor, has been 
recommended.  
Sources:  
Rugo HS, Rumble RB, Macrae E, et al. 
Endocrine therapy for hormone receptor-
positive metastatic breast cancer: 
American Society of Clinical Oncology 
Guideline. J Clin Oncol. 2016;34:3069-
3103. 
Papakonstantinou A, Foukakis T, 
Rodriguez-Wallberg KA, et al. Is 
estradiol monitoring necessary in 
women recieving ovarian suppression 
for breast cancer. J Clin Oncol. 
2016;34:1573-1579. 
Before the PALOMA-3 study, trials of 
clinical importance to investigate the 
effects of endocrine-based therapies on 
advanced breast cancer have been 
designed to only permit the 
participation of postmenopausal 
women, or less commonly, women who 
reach menopause prematurely owing to 
treatment-related ovarian failure.  
Source:  
Cristofanilli M, Turner NC, 
Bondarenko I, et al. Fulvestrant plus 
palbociclib versus fulvestrant plus 
placebo for treatment of hormone-
receptor-positive, HER2-negative 
metastatic breast cancer that progressed 
on previous endocrine therapy 
(PALOMA-3): final analysis of the 
multicentre, double-blind, phase 3 
randomised controlled trial. Lancet 
Oncol 2016;17:425-439.  
 
Questions persist because clinically 
important data are lacking in the 
current era to demonstrate the effects 
of endocrine therapy on 
premenopausal women with ABC. 
Premenopausal women with heavily-
pretreated HR+ ABC and prior 
disease progression because of 
endocrine resistance require 
additional targeted treatment options 
that can extend the duration of an 
effective endocrine-based therapy 
with a tolerable safety profile and 
delay the need for chemotherapy if a 
rapid response is not required.  
Source:  
Rugo HS, Rumble RB, Macrae E, et 
al. J Clin Oncol. 2016;34: 3069-
3103. 
Reinert T, Barrios CH. Optimal 
managment of hormone receptor 
positive metastatic breast cancer in 
2016. Ther Adv Med Oncol. 
2016 ;7:304-320. 
 
Explain why palbociclib in 
combination with endorcine 
therapy and ovarian suppression 
should be considered for 
premenopausal women with prior 
endocrine-resistant HR+ ABC. 
Discuss the risk-benefit profile of 
treating premenopausal women 
with prior endocrine-resistant 
HR+ ABC with palbociclib plus 
fulvestrant and a LHRHa. 
 
Describe why the addition of 
palbociclib does not affect the 
ovarian suppression provided by 
LHRHa. 
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National Comprehensive Cancer 
Network. Clinical Practice Guidelines in 
Oncology (NCCN Guidelines). Breast 
Cancer. Version 1.2016.  
ABC, advanced breast cancer; HR+, hormone receptorpositive; LHRHa, luteinizing hormone‒releasing hormone agonist, MBC, 
metastatic breast cancer. 
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INTRODUCTION 
Many women presenting with early breast cancer (BC) are premenopausal; upon relapse with 
advanced BC (ABC) most are postmenopausal, predominantly as a result of cytotoxic therapy 
and extended endocrine therapy (ET) treatment,[1] or via natural changes. Although younger 
women represent a low percentage of the patients diagnosed with breast cancer (20−34 years, 
1.8%; 35−44 years, 8.9%),[2] presentation of early stage cancer at ≤40 years is prognostic in 
luminal breast cancer with the risk for relapse.[3,4] Survival outcomes are also worse for women 
<40 years than older age groups, notwithstanding intense treatment regimens.[3] 
De novo metastatic and relapsed breast cancer can also occur in peri/premenopausal women 
(hereafter referred to as premenopausal women).[5,6] Yet premenopausal women have generally 
been excluded from large registrational trials involving hormonal agents to asses hormone-
positive ABC; clinical data for premenopausal women remain remarkably limited to only a few 
small phase 2 trials.[7-9] 
Endocrine resistance continues to pose serious clinical challenges.[10] Sequential ET is generally 
the preferred treatment for women with hormone receptor–positive (HR+) human epidermal 
growth factor receptor 2−negative (HER2) metastatic BC.[11] Premenopausal women can 
benefit from ovarian suppression as part of their ET. Options include oophorectomy, 
radiotherapy[12], or medical suppression [13] with a luteinizing hormone‒releasing hormone 
agonist. Although tamoxifen is used as the first-line ET for premenopausal women with HR+ BC 
(preferably with ovarian suppression[14]), aromatase inhibitors (AIs) plus luteinizing hormone‒
releasing hormone agonists can be more effective.[11,15] Fulvestrant, a pure estrogen receptor 
(ER) antagonist and selective ER degrader devoid of estrogenic effects[16] has not been standard 
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treatment for premenopausal women because of limited data supporting its biological effects.[17] 
In a neoadjuvant study of 66 premenopausal women with ER+ BC receiving 250 mg fulvestrant 
as monotherapy, fulvestrant did not significantly alter markers of hormone sensitivity (ER, 
progesterone receptor, and Ki67)[18] as it did in postmenopausal women.[19] Conversely, 750 
mg fulvestrant did elicit significant changes in the same markers, similar to changes observed in 
premenopausal women treated with tamoxifen, suggesting a potential need for higher doses of 
fulvestrant in premenopausal women.[20]  
When used in combination with ET, palbociclib, a selective inhibitor of cyclin-dependent kinases 
4 and 6, resulted in a significant improvement in progression-free survival (PFS) compared with 
ET alone in both treatment-naive BC (PALOMA-1 trial: letrozole vs letrozole + palbociclib[21]; 
PALOMA-2 trial: letrozole + placebo vs letrozole + palbociclib[22]) and in women pretreated
 
for
 
HR+/HER2– ABC (PALOMA-3 trial: fulvestrant vs fulvestrant + palbociclib[6,23]). 
In the randomized, phase 3 PALOMA-3 trial, palbociclib plus fulvestrant (± goserelin) 
prolonged investigator-assessed PFS compared with placebo plus fulvestrant (± goserelin) in 
women with HR+/HER2– ABC after prior progression on ET (median PFS 9.5 vs 4.6 months, 
respectively, hazard ratio, [HR] 0.46 [95% CI: 0.36–0.59], 2-sided log-rank P<.0001).[6] 
PALOMA-3 was the first registrational study to include premenopausal women in this setting; 
herein we describe the results by menopausal status, with a focus on premenopausal women with 
prior endocrine-resistant HR+/HER2 ABC. 
 
PATIENTS AND METHODS 
PALOMA-3 Study Design and Patients 
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The design of the PALOMA-3 phase 3, randomized, double-blind, placebo-controlled trial and 
definitions of the efficacy and safety parameters assessed have been described in detail 
elsewhere.[6,23] Key eligibility criteria include women ≥18 years with HR+/HER2 ABC 
whose disease had progressed on prior ET. One previous line of chemotherapy in advanced 
disease was allowed. Women were defined as premenopausal if they did not meet the criteria for 
postmenopausal status, defined as age ≥60 years, age <60 years and amenorrhea for ≥12 
consecutive months (excluding an alternative pathologic or physiologic cause), and serum 
estradiol (E2) and follicle-stimulating hormone (FSH) concentrations within the laboratory 
reference range for postmenopausal women, documented bilateral oophorectomy, or medically 
confirmed ovarian failure.  
 
Patients were randomized 2:1 to receive palbociclib (125 mg/d orally, 3 weeks on, 1 week off) 
plus fulvestrant (500 mg intramuscularly on day 1 and 15 of cycle 1 and once every 28-day cycle 
thereafter) or placebo plus fulvestrant. Premenopausal patients were required to receive a 
luteinizing hormone‒releasing hormone agonist  subcutaneously every 28 days starting ≥4 weeks 
before study treatment, and upon starting treatment any patients using an luteinizing hormone‒
releasing hormone agonist other than goserelin were switched to goserelin. Randomization was 
stratified by menopausal status, visceral metastases, and sensitivity to prior hormonal 
therapy.[6,23]  
Biochemical assessments were performed on blood samples collected from premenopausal 
women on day 15 of study treatment. Plasma E2 analysis was conducted by InVentiv Health 
(Burlington, MA, USA) using gas chromatography (GC)/tandem mass spectrometry (MS-MS). 
The lower limit of quantification was 0.625 pg/mL. LH and FSH were measured at the Royal 
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Marsden Hospital by immunoradiometric assay (MG12151, IBL International, Hamburg, 
Germany; KIP0841, DIAsource, Ottignies-Louvain-la-Neuve, Belgium). The kit-reported 
detection limits were 0.2 and 0.1 mIU/mL, respectively. 
Plasma pharmacokinetic (PK) samples were drawn predose on days 1 and 15 of cycles 1 and 2 
and on day 1 of cycle 3 for the assessment of trough concentrations (Ctrough) of palbociclib, 
fulvestrant, and goserelin (when applicable) in a subgroup of ~40 patients included in an initial 
interim safety assessment. Additional PK samples for plasma Ctrough of palbociclib were drawn 
on day 15 of cycles 1 and 2 from all remaining patients.  
 
Statistical Analysis 
The Kaplan-Meier method[24] was applied to estimate median PFS (mPFS) and generate 
survival curves. A 2-sided unstratified log-rank test was used to compare treatment arms by 
menopausal status and a 1-sided unstratified log-rank test was used to compare treatment arms in 
subsets of premenopausal and postmenopausal patients ≤50 years as part of an exploratory 
analysis. The hazard ratio was estimated from the Cox proportional hazards regression model. 
Clinical benefit response (CBR) and objective response rate were evaluated and compared 
between treatment arms using a 1-sided exact test stratified by the presence of visceral 
metastases and sensitivity to prior hormonal therapy per randomization. A multivariate analysis 
was run to evaluate the relationship between baseline prognostic factors with PFS. The final 
explanatory variables for the model were acquired using a backward selection process with a 0.1 
significance level required for retaining the effects in the model. Descriptive analysis was used to 
summarize maximum-grade treatment-emergent adverse events (AEs). Biochemistry data were 
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summarized and t tests (one for each hormone) were used to compare data between treatment 
arms without a multiplicity adjustment for these or other exploratory analyses. The analyses for 
the potential for drug-drug interactions (DDIs) are described in detail in the appendix 
(supplementary text, online only). Statistical analyses were performed using SAS
®
 Version 9.2 
(SAS Institute, Cary, NC).  
Before any study procedures were initiated, all patients provided written informed consent. 
Institutional review boards at participating centers approved all study-related procedures, which 
were conducted in accordance with the International Conference on Harmonisation, the 
guidelines for Good Clinical Practice, and the Declaration of Helsinki. Study enrollment is 
closed and the trial met its primary endpoint at interim analysis. The overall survival follow-up is 
in progress. 
 
RESULTS 
Between October 7, 2013, and August 26, 2014, 521 patients were randomly assigned to receive 
palbociclib plus fulvestrant (347 patients) or placebo plus fulvestrant (174 patients) with or 
without goserelin[6] (Appendix Fig. A1, online only).  
 
Patient Demographics 
A total of 108 (21%) women were premenopausal and 413 (79%) were postmenopausal. Overall, 
42 (8%) women were ≤40 years, and 163 (31%) women were ≤50 years. Among premenopausal 
women, the mean age was 45 years; 83 (80%) of these patients were ≤50 years. Among 
postmenopausal women, 80 (19%) patients were aged ≤50 years. Demographic and baseline 
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characteristics are shown by menopausal status in Table 1. Half of the premenopausal women 
had received both tamoxifen and AI before enrollment. Baseline characteristics between 
treatment arms within menopausal subgroups were well balanced, except more premenopausal 
women had 2 prior lines of therapy in the ABC setting in the palbociclib than in the placebo arm 
(31.9% and 19.4%, respectively). Baseline characteristics between premenopausal and 
postmenopausal women were also well balanced, although the ESR1 mutation rate by cfDNA 
was slightly lower in premenopausal women.  
 
Efficacy 
The data cutoff for this analysis was March 16, 2015, corresponding with the final primary 
efficacy analysis of PFS for the overall intent-to-treat population.[6] Investigator-assessed mPFS 
for palbociclib plus fulvestrant vs placebo plus fulvestrant in the premenopausal subgroup was 
9.5 vs 5.6 months, respectively (hazard ratio, 0.50 [95% CI: 0.290.87], 2-sided P=.013). In the 
postmenopausal subgroup, mPFS was 9.9 vs 3.9 months (hazard ratio, 0.45 [0.34–0.59], 2-sided 
P<.0001). Kaplan-Meier survival curves for PFS are shown for premenopausal women in Fig. 
1.[25]  
In the palbociclib arm vs the placebo arm, investigator-assessed objective responses were 
observed in 25.0% (18/72) vs 11.1% (4/36) of premenopausal patients, respectively (odds ratio, 
3.06 (95% CI: 0.8213.38), P=.057; Fig. 2[26]). Significant improvement occurred with 
palbociclib plus fulvestrant vs placebo plus fulvestrant in investigator-assessed CBR, which was 
observed in 69.4% (50/72) vs 44.4% (16/36) of premenopausal women (OR 2.89 [95% CI: 
1.157.34], P=.011).  
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Of those premenopausal women who underwent subsequent chemotherapy after disease 
progression, 58.6% (17/29) had received palbociclib plus fulvestrant whereas 78.3% (18/23) had 
received placebo plus fulvestrant. The median time to first chemotherapy treatment, relative to 
the date of randomization, was 120.0 (range, 37‒354) days for women in the palbociclib arm and 
74.5 (53‒240) days for those in the placebo arm. 
Exploratory Findings in Pre- and Postmenopausal Women ≤50 Years Old  
Among premenopausal women aged ≤50 years (n=83), mPFS was 9.5 months in the palbociclib 
arm and 5.6 months in the placebo arm (hazard ratio, 0.53 [95% CI: 0.280.99], 1-sided 
unstratified log-rank test, P=.022; Fig 1B). Among postmenopausal women ≤50 years (n=80) in 
the palbociclib arm compared with the placebo arm, mPFS was 7.7 vs 4.5 months, respectively 
(hazard ratio, 0.49 [0.270.89], 1-sided unstratified log-rank test, P=.008; Fig 1C).  
Prognostic Factors 
Important and favorable prognostic factors in the final Cox proportional hazards multivariate 
model included absence of visceral disease for both premenopausal and postmenopausal patient 
subpopulations and Asian ethnicity for premenopausal patients. The treatment effect of 
palbociclib plus fulvestrant seen in the primary analysis of PFS held when the important 
prognostic factors were simultaneously adjusted in the multivariate analyses for both 
premenopausal and postmenopausal patients (Table 2). When BMI was examined with the 
treatment arm in a separate multivariate model, lower values were more favorable for PFS.   
 
Safety 
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Although all premenopausal women received goserelin concurrently with palbociclib plus 
fulvestrant, the safety profile was similar to that of postmenopausal women in terms of the type 
and frequency of AEs (all grades and grade 34), serious AEs (SAEs), the rate of dose 
reductions, cycle delays. Dose interruptions and discontinuation rate due to AEs were also 
similar for the palbociclib arm between menopausal subgroups (premenopausal, 5.6% and 
postmenopausal, 4.7%) (Table 3).  
 
Biochemical Analysis 
After 15 days of study treatment, there was no significant difference in the mean concentrations 
of LH, FSH, or plasma E2 between those premenopausal patients receiving palbociclib or not; all 
unadjusted P values from the t tests were >0.05 (Fig. 3). Mean E2 concentrations were consistent 
with those expected in the postmenopausal range. One patient in the palbociclib arm had an E2 
value of 93.5 pg/mL, more than 3 times the upper limit of that group and not consistent with 
ovarian suppression. There was a statistically significant correlation between plasma E2 levels 
and body mass index (BMI) in both treatment arms (Spearman’s rho = .44, P=.002 and .49, 
P=.02, respectively).  
Drug-Drug Interaction Assessment 
Results of the 1-way analysis of variance (ANOVA) and analysis of covariance (ANCOVA) 
analyses conducted to investigate the potential for DDIs among palbociclib, fulvestrant, and 
goserelin are shown in Appendix Table A1 (online only). The ratio of the adjusted geometric 
means (90% CI) for palbociclib from the final ANCOVA model and the within-patient mean 
steady-state concentration trough (CtroughSS) in the presence and absence of goserelin was 88.3% 
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(78.6%99.1%). The ratio of the adjusted geometric means (90% CI) for goserelin within-patient 
mean CtroughSS in the presence and absence of palbociclib was 110% (54.2%–225%). For the ratio 
of the adjusted geometric means (90% CI) for palbociclib from the final ANCOVA model, the 
within-patient mean CtroughSS in the presence and absence of fulvestrant was 128% 
(117%140%). The ratio of the adjusted geometric means (90% CI) for fulvestrant within-
patient mean CtroughSS in the presence and absence of palbociclib was 122% (101%–147%).  
 
DISCUSSION 
We report the results of the largest cohort of premenopausal women with prior endocrine-
resistant HR+/HER2− ABC ever studied. The study found that premenopausal patients who 
received palbociclib plus fulvestrant significantly benefited compared with patients treated with 
placebo plus fulvestrant, consistent with the benefit observed for postmenopausal women. In 
premenopausal and postmenopausal women aged ≤50 years, PFS favored the palbociclib arm 
compared with the placebo arm, regardless of menopausal status and luteinizing hormone‒
releasing hormone agonist therapy.  
Among all postmenopausal women, only 9 (2.2%) were ≤40 years and 71 (17.2%) were aged 
>4050 years. The majority of these women possibly became postmenopausal as a result of 
previous chemotherapy for either primary or ABC, or ovarian suppression, a scenario more 
likely to occur in women >40 years whose ovarian function is inherently less resilient to such 
treatment.[27] Breast cancer incidence has been shown to peak in Asian women at a younger age 
compared with women from Western countries.[28] As expected, the proportion of Asian women 
 16 
 
with ABC who were premenopausal (41% [44/108]) was at least 2-fold higher than for 
postmenopausal women (15% [61/413]) in this study. 
Until recently, premenopausal women with HR+ metastatic BC who are candidates for ET were 
mainly treated with tamoxifen, with or without a luteinizing hormone‒releasing hormone 
agonist. In a small study of 26 patients, median age 44 (range, 3051) years, 250 mg fulvestrant 
(dose currently suboptimal) plus goserelin as first- to fourth-line therapy was reported to provide 
promising activity.[29]
 
As an estrogen receptor downregulator, fulvestrant, unlike tamoxifen, is 
not efficacious in premenopausal women unless it is administered in combination with ovarian 
suppression.[30] 
 
In addition, a number of small phase 2 studies have shown the efficacy of AI 
treatment concurrent with luteinizing hormone‒releasing hormone agonists.[7,8,31] The addition 
of a luteinizing hormone‒releasing hormone agonist to tamoxifen or AIs has been shown to 
improve efficacy in early as well as ABC.[14,15,27,32,33] PALOMA-3 is the only phase 3 study 
to date to report outcomes data for fulvestrant 500 mg with ovarian suppression in 
premenopausal patients.
[6]
 In premenopausal women in the control arm, mPFS with fulvestrant 
was 5.6 months. Accordingly, the fulvestrant label approved by the US Food and Drug 
Administration was recently expanded to include premenopausal women who receive concurrent 
ovarian suppression.[34]  
Because of the low potential for a DDI between the protocol-specified concomitant medications 
and palbociclib based on their metabolic pathways and ability to affect the activity of relevant 
metabolic enzymes, this study was designed with the intention of confirming the lack of 
clinically significant DDIs using a sparse PK sample collection (CtroughSS only) for each analyte. 
The magnitude of the ratios of the adjusted geometric means for the ANOVA and ANCOVA 
DDI analyses was not considered to represent a clinically meaningful difference.   
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The PK data confirms there were no clinically significant metabolic DDIs between palbociclib 
and goserelin or between palbociclib and fulvestrant when these 2 drugs were coadministered. 
Furthermore, the
 
coadministration of goserelin did not have a clinically significant impact on 
fulvestrant plasma PK. 
The clinical effectiveness of luteinizing hormone‒releasing hormone agonists depends on their 
suppression of ovarian steroidogenesis. There is evidence that although these agents achieve 
complete cessation of ovarian E2 synthesis by the end of the first month of treatment, partial 
recovery can occur in some patients, apparently driven by progressive recovery of FSH 
levels.[35] Combining a luteinizing hormone‒releasing hormone agonist with fulvestrant could 
still potentially result in incomplete ovarian suppression if E2 and FSH levels increase in 
response to fulvestrant.[35] We report hormonal concentrations measured after 15 days of 
fulvestrant treatment but after ≥6 weeks on goserelin, given goserelin was started 4 weeks before 
the study commenced. It is also important to note that the levels of E2 were measured with a 
highly sensitive GC/MS-MS, which avoids cross reactions with fulvestrant or its metabolites that 
can lead to highly aberrant values that more commonly occur using immunoassays.[36,37] Only 
one of 48 patients (2%) treated with palbociclib plus fulvestrant had an E2 value that was clearly 
premenopausal, but otherwise the values assessed for all patients were consistent with full 
ovarian function suppression, and there was no difference associated with the addition of 
palbociclib. This is supported by the significant relationship between plasma E2 levels and BMI; 
extragonadal estrogen production occurs mainly in subcutaneous fat[38] and resulting plasma 
concentrations are known to correlate with BMI.[39] Accordingly, there was no disruption of the 
correlation with the addition of palbociclib treatment. This underlines that the effect of 
palbociclib is independent of the background ET and supports the rationale for the concurrent 
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use of luteinizing hormone‒releasing hormone agonists with ET in other studies currently 
recruiting participants.[40,41]  
From a safety perspective, the incidence of any-grade and grade 3‒4 AEs and SAEs was similar 
between premenopausal and postmenopausal women who received palbociclib plus fulvestrant, 
despite the addition of goserelin to the regimen. Dose modifications of palbociclib were also 
similar between premenopausal and postmenopausal groups.  
Conclusions 
The palbociclib plus fulvestrant regimen, with the addition of goserelin, essentially enables 
premenopausal women to be treated in close accordance with the guidelines for postmenopausal 
women, as recommended by the NCCN.[30] These findings show that the addition of palbociclib 
had no impact on the concentration of fulvestrant, complete ovarian suppression was maintained, 
and no additional toxicities were evident with the addition of a luteinizing hormone‒releasing 
hormone agonist, all factors important for the investigation of palbociclib in early stage breast 
cancer. The results support the use of palbociclib in combination with fulvestrant and goserelin 
for women with HR+ ABC, and these findings have expanded the treatment options for 
premenopausal women. 
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Figure Legends 
 
Figure 1. Investigator-assessed PFS by treatment for the intent-to-treat subpopulations of (A) 
premenopausal women, (B) premenopausal women, age ≤50 years, and (C) postmenopausal 
women age ≤50 years. PFS was defined as the time from the date of randomization to the date or 
the first documentation of objective progression of disease or death due to any cause in the 
absence of documented progressive disease, whichever occurred first. PFS data were censored on 
the date of the last tumor assessment on study for patients who did not have objective tumor 
progression and who did not die while on study. CI was calculated based on the Brookmeyer and 
Crowley method.[25] 
CI, confidence interval; NE, not estimable; PFS, progression-free survival. 
  
Figure 2.  Investigator-assessed confirmed objective response and clinical benefit rate in 
premenopausal women.  
CBR, clinical benefit response; CI, confidence interval; CR, complete response; OR, odds ratio; 
ORR, objective response rate; PR, partial response; SD, stable disease ≥24 week. 
a
1-sided exact test stratified by the presence of visceral metastases and sensitivity to prior 
hormonal therapy per randomization. 
b
CBR was CR or PR or stable disease ≥24 weeks. 
c
CI was calculated using the exact (Clopper-Pearson) method.[26] 
 
Figure 3. Biochemical plasma analyses for premenopausal women on day 15. 
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Abbreviations: E2, estradiol; FSH, follicle-stimulating hormone; IQR, interquartile range; LH, 
luteinizing hormone; max, maximum; min, minimum. 
a
Six patients had E2 concentrations that were not considered valid (ie, below the 
quantification limit of 1.25 pg/mL or a volume too small for reanalysis). 
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Tables 
Table 1. Baseline Patient and Disease Characteristics for Premenopausal and Postmenopausal Patients 
Randomly Assigned in PALOMA-3 
 Premenopausal 
(n=108) 
 Postmenopausal 
(n=413) 
Total 
(N=521)
a
 
 
Palbociclib 
+ 
Fulvestrant 
(n=72) 
Placebo 
+ 
Fulvestrant 
(n=36)  
Palbociclib  
+ 
Fulvestrant 
(n=275) 
Placebo 
+ 
Fulvestrant 
(n=138) 
 
Characteristic No. (%) No. (%)  No. (%) No. (%)  
Age, y        
≤40 25 (34.7) 8 (22.2)  7 (2.5) 2 (1.4)    42 (8.1) 
>4050 29 (40.3) 21 (58.3)  47 (17.1) 24 (17.4) 121 (23.2) 
>50 18 (25.0) 7 (19.4)  221 (80.4) 112 (81.2) 358 (68.7) 
Race       
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Asian 31 (43.1) 13 (36.1)  43 (15.6) 18 (13.0) 105 (20.2) 
White 37 (51.4) 21 (58.3)  215 (78.2) 112 (81.2)  385 (73.9) 
Black and other 4 (5.6) 2 (5.6)  17 (6.2) 8 (5.8)     31 (6.0) 
Measurable disease 
present
b
 
  
 
   
Yes 55 (76.4) 26 (72.2)  213 (77.5) 112 (81.2) 406 (77.9) 
No 17 (23.6) 10 (27.8)  62 (22.6) 26 (18.8) 115 (22.1) 
Visceral disease         
Yes 45 (62.5) 23 (63.9)  161 (58.5) 82 (59.4) 311 (59.7) 
No 27 (37.5) 13 (36.1)  114 (41.5) 56 (40.6) 210 (40.3) 
Prior lines of endocrine 
therapy  
  
 
   
1 34 (47.2) 17 (47.2)  126 (45.8) 74 (53.6) 251 (48.2) 
2 31 (43.1) 13 (36.1)  109 (39.6) 48 (34.8) 201 (38.6) 
≥3 7 (9.7) 6 (16.7)  40 (14.5) 16 (11.6) 69 (13.2) 
Prior lines of therapy in       
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advanced/metastatic setting 
0 18 (25.0) 9 (25.0)  56 (20.4) 31 (22.5) 114 (21.9) 
1 24 (33.3) 17 (47.2)  117 (42.6) 66 (47.8) 224 (43.0) 
2 23 (31.9) 7 (19.4)  71 (25.8) 30 (21.7) 131 (25.1) 
≥3 7 (9.7) 3 (8.3)  31 (11.3)   11 (8.0)   52 (10.0) 
Purpose of most recent 
treatment   
72 (100) 36 (100) 
 
275 (100) 137 (99.3) 520 (99.8) 
Adjuvant therapy 18 (25.0) 9 (25.0)  56 (20.4) 31 (22.5) 114 (21.9) 
Advanced or metastatic 
breast cancer 
54 (75.0) 27 (75.0) 
 
219 (79.6) 106 (76.8) 406 (77.9) 
Disease-free interval, mo 49 (68.1) 25 (69.4)  184 (66.9) 98 (71.0) 356 (68.3) 
>24  38 (52.8) 20 (55.6)  154 (56.0) 81 (58.7) 293 (56.2) 
12–24 10 (13.9) 5 (13.9)  20 (7.3) 14 (10.1)     49 (9.4) 
<12
c
 1 (1.4) 0  10 (3.6) 3 (2.2)     14 (2.7) 
Prior endocrine therapy
d
        
Aromatase inhibitors only 1 (1.4) 2 (5.6)  136 (49.5) 68 (49.3) 207 (39.7) 
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Tamoxifen only 38 (52.8) 17 (47.2)  13 (4.7) 6 (4.3) 74 (14.2) 
Aromatase inhibitors and 
tamoxifen 
33 (45.8) 17 (47.2) 
 
126 (45.8) 64 (46.4) 240 (46.1) 
Most recent therapy
e
       
Aromatase inhibitors + 
LHRH  
3 (4.2) 1 (2.8) 
 
0 0 4 (<1.0) 
Tamoxifen + LHRH  2 (2.8) 1 (2.8)  0 1 (0.7) 4 (<1.0) 
Tamoxifen 31 (43.1) 14 (38.9)  28 (10.2) 13 (9.4) 86 (16.5) 
Previous chemotherapy in 
metastatic setting
f
 
  
 
   
Treatment of metastatic 
disease ± neoadjuvant 
therapy  
23 (31.9) 12 (33.3) 
 
90 (32.7) 52 (37.7) 177 (34.0) 
Previous sensitivity to 
endocrine therapy
g
 
  
 
   
Yes 51 (70.8) 25 (69.4)  223 (81.1) 111 (80.4) 410 (78.7) 
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Abbreviations: cfDNA, circulating free DNA; ER, estrogen receptor; ESR1, estrogen receptor 1; LHRH, luteinizing 
hormone-releasing hormone; PI3K, phosphoinositide 3-kinase; PR, progesterone receptor. 
a
Due to rounding, some percentages may not total to exactly 100%.  
b
At least 1 target lesion ≥20 mm by conventional techniques or at least 1 target lesion >10 mm for spiral CT. 
No  21 (29.2) 11 (30.6)  52 (18.9) 27 (19.6) 111 (21.3) 
Biomarker status by local 
assessment  
67 (100) 34 (100) 
 
265 (100) 127 (100) 493 (100) 
ER+/PR+ 49 (68.1) 25 (69.4)  191 (69.5) 86 (62.3) 351 (67.4) 
ER+/PR 18 (25.0) 9 (25.0)  74 (26.9) 41 (29.7) 142 ( 28.8) 
PI3K mutation status by 
cfDNA
h
 
53 (100) 26 (100) 
 
212 (100) 104 (100) 395 (100) 
Positive 22 (41.5) 9 (34.6)  63 (29.7) 35 (33.7) 129 (32.7) 
Negative 31 (58.5) 17 (65.4)  149 (70.3) 69 (66.3) 266 (67.3) 
ESR1 mutation status by 
cfDNA
h
 
53 (100) 26 (100) 
 
212 (100) 105 (100) 396 (100) 
Positive 9 (17.0) 6 (23.1)  58 (27.4) 33 (31.4) 106 (26.8) 
Negative 44 (83.0) 20 (76.9)  154 (72.6) 71 (67.6) 289 (73.0) 
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c
One subject with negative duration included in <12 months category. 
d
Premenopausal women had to have documented progression while on or within 12 months of completion of adjuvant 
therapy with tamoxifen whereas postmenopausal women had to have similarly progressed on an aromatase inhibitor.
 
e
Values are mutually
 
exclusive. Not all most recent prior therapies are shown. 
f
Subjects are counted for each treatment of metastatic disease (± neoadjuvant) received. 
g
Sensitivity to prior hormonal therapy was defined as either (i) documented clinical benefit (complete response, partial 
response, stable disease ≥24 weeks) to ≥1 prior hormonal therapy in the metastatic setting, or (ii) ≥24 months of 
adjuvant hormonal therapy prior to recurrence.
 
h
Not all patients had cfDNA samples; the data represent a subset of patients only. 
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Table 2. Multivariate Analyses of the Association of Baseline
a
/Prognostic Factors With Progression-Free Survival 
 Premenopausal
b
 
 
Postmenopausal 
Treatment  
Palbociclib + 
Fulvestrant  
(n=72) 
Placebo +  
Fulvestrant 
(n=36) 
Palbociclib + 
Fulvestrant 
(n=275) 
Placebo +  
Fulvestrant  
(n=138) 
Subjects Who Had Disease 
Progression or Death, No. (%) 
30 (41.7) 23 (63.9) 115 (41.8) 91 (65.9) 
 
Hazard 
Ratio
c
 95% CI P
d
  
Hazard 
Ratio
c
 95% CI P
d
 
Baseline/prognostic factors
  
        
Treatment arm        
Palbociclib vs placebo 0.495 0.2870.855 .0117  0.442 0.3350.584 <.0001 
Visceral disease        
Yes vs no 2.751 1.4225.325 .0027  1.708 1.2792.283 .0003 
Race        
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Abbreviations: AI, aromatase inhibitor; CI, confidence interval; NA, not available. 
Palbociclib arm, palbociclib + fulvestrant; placebo arm, placebo + fulvestrant.  
a
Baseline factors that entered the model selection included visceral disease (yes vs no), time from first diagnosis to relapse 
(≤24 months vs >24 months vs NA), prior treatment (AIs vs non-AIs), prior chemotherapy (yes vs no), prior endocrine 
therapy (1 line vs >1 line), race (Asian vs non-Asian [white, black and other]). 
b
Premenopausal status is per randomization.  
c
A hazard ratio <1 indicates a reduced hazard in the first category, whereas a hazard ratio >1 indicates a reduced hazard on the 
last category of the variable. 
d
2-sided P value, bold indicates significant at the threshold of P<.05.  
Asian vs non-Asian (white, 
black, and other) 
0.485 0.2700.870 .0152     
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Table 3. Summary and Listing of Treatment-Emergent AEs (All Causalities, All Cycles) Occurring in ≥10% Patients in Any 
Treatment Arm and Dose Modifications Due to AEs by Menopausal Subgroup and Treatment  
  Premenopausal  Postmenopausal 
  Palbociclib + 
Fulvestrant 
(n=71) 
 Placebo +  
Fulvestrant 
(n=36) 
 
 Palbociclib + 
Fulvestrant 
(n=274) 
Placebo + 
Fulvestrant 
(n=136) 
AEs, %
ab
         
Any AEs  98.6  97.2   98.5 87.5 
All grade 3/4 AEs  83.1  25.0   71.2 22.1 
Any serious AEs  14.1  19.4   12.4 16.9 
All grade 3/4 serious AEs  8.5  8.3   9.1 11.8 
Dose modifications due to AEs, %       
Dose interruption   90.1  58.3   82.1 62.5 
Dose reduction    42.3  2.8   31.8 1.5 
Cycle delay   52.1  22.2   46.7 8.8 
Discontinuation rate  
  of palbociclib/placebo  
 
5.6 
 
0  
 
4.7 3.7 
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Average daily dose of palbociclib/placebo, mg
c
      
Median (range)  125 (85–126)  125 (110–126)    125 (80–131)  125 (106–129) 
AEs, %
ab
 
All 
Gr
e
 Gr 3 Gr 4  
All 
Gr Gr 3 Gr 4  
All 
Gr
e
 Gr 3 Gr 4  
All 
Gr
e
 Gr 3 Gr 4 
Hematologicd                
Neutropenia 85.9 60.6 15.5  5.6 0 0  79.6 53.3 8.4  2.9 0 0.7 
Leukopenia 56.3 32.4 1.4  2.8 0 0  47.8 25.5 0.4  4.4 0.7 0.7 
Anemia 21.1 2.8 0  5.6 0 0  29.6 2.9 0  12.5 2.2 0 
Thrombocytopenia 19.7 2.8 0  ― ― ―  21.5 1.5 0.7  ― ― ― 
Nonhematologic                
Infectionsd 47.9 1.4 1.4  33.3 2.8 0  40.1 1.8 0  29.4 2.9 0 
Nausea 40.8 0 ―  36.1 0 ―  30.3 0 ―  25.0 0.7 ― 
Stomatitisd 36.6 1.4 0  16.7 0 0  24.8 0.4 0  12.5  0 0 
Fatigue 35.2 0 ―  30.6 0 ―  40.1 2.9 ―  27.9 1.5 ― 
Diarrhea 26.8 0 0  16.7 2.8 0  20.1 0 0  19.1 0 0 
Vomiting 23.9 0 0  25.0 0 0  15.0 0.4 0  11.8 0.7 0 
Headache 22.5 0 ―  25.0 0 ―  23.4 0.7 ―  17.6 0 ― 
Back pain 21.1 0 ―  22.2 5.6 ―  13.1 1.5 ―  15.4 0.7       ― 
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Arthralgia 19.7 0 ―  16.7 0 ―  12.8 0.4 ―  15.4 0 ― 
Constipation 19.7 0 0  19.4 0 0  19.0 0 0  14.7 0 0 
Decreased appetite 16.9 0 0  11.1 0 0  14.6 1.1 0  7.4 0.7 0 
Rashd 16.9 0 0  2.8 0 0  14.6 0.7 0  5.9 0 0 
Alopecia 15.5 ― ―  5.6 ― ―  17.5 ― ―  6.6 ― ― 
Hot flush 15.5 0 ―  16.7 0 ―  15.3 0 ―  16.9 0.7 ― 
Pyrexia 15.5 0 0  13.9 0 0  9.9 0.4 0  2.9 0 0 
Dizziness 14.1 1.4 ―  16.7 0 ―  11.3 0 ―  7.4 0 ― 
Insomnia 14.1 1.4 ―  5.6 0 0  8.4 0 0  7.4 0 0 
Oropharyngeal pain 14.1 0 0  11.1 0 0  9.9 0 0  5.9 0 0 
Cough 11.3 0 ―  13.9 0 ―  15.7 0 ―  12.5 0 ― 
Abdominal pain upper 2.8 0 0  16.7 0 0  ― ― ―  5.1 0 0 
Abdominal pain 7.0 0 ―  13.9 0 ―  8.4 0.7 ―  3.7 0.7 ― 
Injection site pain 2.8 0 0  13.9 0 0  7.3 0.4 0  8.8 0 0 
Pain in extremity 8.5 0 ―  13.9 2.8 ―  13.5 0 ―  11.8 1.5 ― 
Asthenia 2.8 0 0  11.1 0 0  8.0 0 0  3.7 0.7 0 
Chest pain 1.4 0 ―  11.1 0 ―  2.6 0.4 ―  5.1 0 ― 
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Abbreviations: AE, adverse event; Gr, grade; n, subjects evaluable for AEs (ie, includes all patients who received ≥1 dose of study treatment 
[palbociclib/placebo or fulvestrant]); PT, preferred term. 
a
Percentages are calculated in reference to n, and values include data up to 28 days after the last dose of study drug.  
b
Events coded using the Medical Dictionary for Regulatory Activities (version 18.0) PTs, including clusters of PTs, and by maximum Common 
Terminology Criteria for Adverse Events grade. 
c
Average daily dose administered = (total dose administered)/(total days on drug). Days on drug is defined as the total number of days on which the 
drug was actually administered. 
d
Clustered PTs: Anemia refers to any event having a PT equivalent to anemia or hematocrit decreased or hemoglobin decreased; infections is any 
event having a PT part of the system organ class infections and infestations; leukopenia is any event having a PT equivalent to leukopenia or white 
blood cell count decreased; neutropenia is any event having a PT equivalent to neutropenia or neutrophil count decreased. Rash is any event having a 
PT equivalent to dermatitis or dermatitis acneiform or rash or rash erythematous or rash maculopapular or rash papular or rash pruritic; stomatitis is 
any event having a PT equivalent to aphthous stomatitis or cheilitis or glossitis or glossodynia or mouth ulceration or mucosal inflammation or oral 
pain or oropharyngeal discomfort or oropharyngeal pain or stomatitis; thrombocytopenia is any event having a PT equivalent to platelet count 
decreased or thrombocytopenia. 
e
Grade 5 events: in the palbociclib plus fulvestrant arm of the study, 2 (2.8%) premenopausal women had disease progression, and 1 (1.4%) 
premenopausal woman with disease progression also had hepatic failure; among postmenopausal women in the palbociclib plus fulvestrant arm, 1 
(0.4%) had disseminated intravascular coagulation and 1 (0.4%) experienced general or physical health deterioration; among postmenopausal women 
in the placebo arm of the study, 1 (0.7%) had acute respiratory distress, 1 (0.7%) had breast cancer, and 1 (0.7%) had a cerebral hemorrhage. 
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Appendix  
Figure A1. CONSORT diagram (online only) 
a
For reasons other than an adverse event. 
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Supplementary Text 
Drug-Drug Interactions  
Potential for drug-drug interactions (DDIs) on the analytes palbociclib, fulvestrant, and goserelin was assessed using a 1-way analysis 
of variance (ANOVA) to analyze the natural log-transformed Ctrough with unique drug combination as a single factor. Additionally, the 
potential for DDIs to affect the PK of palbociclib was assessed using an analysis of covariance (ANCOVA) model to analyze the 
natural log-transformed Ctrough with unique drug combination as a main effect along with age and baseline body weight, the only 
covariates found to be statistically significant in a prior palbociclib population PK model,[42] were covariates in the full model. 
Regression analyses were performed on the natural log-transformed Ctrough against unique drug combinations, and covariates identified 
using a backward selection process remained in the final ANCOVA model. The input for each statistical model was the within-patient 
mean of 2 steady-state (SS) Ctroughs for each analyte. For analyses using palbociclib PK, data from PALOMA-3 comprised the test 
group and historical data comprised the reference group. For analyses using fulvestrant and goserelin, PK comparisons were made 
across palbociclib and placebo treatment arms. A data cutoff of December 5, 2014 was used for the analyses of potential DDIs.
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Table A1.  Statistical Summary of Treatment Comparisons for Within-Patient Mean CtroughSS, Assessment of 
DDI Potential Between Palbociclib, Fulvestrant, and Goserelin (PALOMA-3; online only) 
Statistical 
Model 
Adjusted Geometric Means
a 
Ratio 
(Test/Reference) 
of Adjusted 
Means
b
 
90% CI 
for Ratio
b
 Test Group Reference Group 
Potential Effect of Goserelin on Palbociclib PK 
 Palbociclib + 
Fulvestrant + 
Goserelin 
(n=43) 
Palbociclib + 
Fulvestrant – 
Goserelin 
(n=174) 
  
ANOVA
c 
72.0 79.7 90.4 (80.2102) 
ANCOVA, full
d
 73.9 79.4 93.1 (81.9106) 
ANCOVA, final
e
 70.6 80.0 88.3 (78.699.1) 
Potential Effect of Fulvestrant on Palbociclib PK 
 Palbociclib + 
Fulvestrant Total 
(n=217) 
Palbociclib Historical 
Data
f
 
(n=98) 
  
ANOVA
c 
75.8 58.8 129 (118141) 
ANCOVA, full
d
 76.6 58.6 131 (119143) 
ANCOVA, final
e
 75.2 58.9 128 (117140) 
Potential Effect of Goserelin on Fulvestrant PK 
 
Palbociclib + 
Fulvestrant + 
Goserelin 
(n=9) 
Palbociclib + 
Fulvestrant − 
Goserelin 
(n=28)  
 
ANOVA
c
 11.1 10.7 103 (79.6134) 
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Statistical 
Model 
Adjusted Geometric Means
a 
Ratio 
(Test/Reference) 
of Adjusted 
Means
b
 
90% CI 
for Ratio
b
 Test Group Reference Group 
 
Placebo + 
Fulvestrant + 
Goserelin 
(n=5) 
Placebo + 
Fulvestrant − 
Goserelin 
(n=14)  
 
ANOVA
c
 10.4 8.4 124 (87.1176) 
Potential Effect of Palbociclib on Fulvestrant PK 
 
Palbociclib + 
Fulvestrant Total 
(n=37) 
Placebo + 
Fulvestrant Total 
(n=19) 
 
 
ANOVA
c
 10.8 8.85 122 (101147) 
Potential Effect of Palbociclib on Goserelin PK 
 
Palbociclib + 
Fulvestrant + 
Goserelin 
(n=9) 
Placebo + 
Fulvestrant + 
Goserelin 
(n=5) 
 
 
ANOVA
c
 303 274 110 (54.2225) 
Abbreviations: ANCOVA, analysis of covariance; ANOVA, analysis of variance; CI, confidence interval; CtroughSS, 
steady-state concentration trough; DDI, drug-drug interactions; PK, pharmacokinetics. 
One outlier was excluded from final analyses using palbociclib PK because the absolute value of the patient’s 
studentized residual was >5 in all statistical models. 
a
Adjusted geometric means for palbociclib and fulvestrant are presented in units of ng/mL, whereas goserelin is 
presented in units of pg/mL. 
b
The ratios and 90% CIs are expressed as percentages. 
c
Based on log-transformed ANOVA with final values back-transformed from the log scale. Unique drug 
combination is the fixed factor. 
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d
Based on log-transformed ANCOVA with final values back-transformed from the log scale. Unique drug combination is the fixed 
factor, with age and baseline weight as the covariates in the full model. 
e
Based on log-transformed ANCOVA with final values back-transformed from the log scale. Unique drug combination is the fixed 
factor, with baseline weight as the only covariate in the final model. 
f
Historical palbociclib PK data are from studies registered with ClinicalTrials.gov identifiers NCT00141297, NCT00420056, 
NCT00721409. 
 
